#HisamitsuPharmaceutical

As a result of the tender offer concluded on February 19, 2026, Taiyo Kosan Co., Ltd. acquired 41,803,599 shares of Hisamitsu Pharmaceutical Co., Inc. (61.81% voting rights), and is expected to become the parent company and principal shareholder.

Taiyo Kosan Co., Ltd. submitted an amended tender offer notification to the Kanto Finance Bureau on February 3, 2026, regarding the tender offer it commenced on January 7, 2026, for shares of Hisamitsu Pharmaceutical Co., Inc., partially correcting the tender offer commencement announcement.

There are reports that the company will be privatized through a management buyout (MBO) worth approximately 450 billion yen; however, this was not announced by the company. The management buyout is under consideration and an official announcement is planned within today.